.jpg){kind=logo}
The 4th International Online Conference on Vaccines
IOCV 2027 is Now OPEN for Abstract Submission and Registration.
Instructions for authors are available online.
Please click the "Submit" button in the upper-right corner of the webpage or click here to submit your abstract.
Please click "Register" button in the upper-right corner of the webpage or click here to save your seat.
For any inquiries, please contact us at iocv2027@mdpi.com.
the chair
We are pleased to announce the 4th International Online Conference on Vaccines (IOCV 2027), which will be held online and promoted by the open access MDPI journal Vaccines (ISSN 2076-393X, IF 3.4).
Vaccines remain one of the most powerful tools in modern medicine, and we stand at a uniquely transformative moment in their development. Cutting-edge technologies, including mRNA platforms, structure-based antigen design, single-cell sequencing, and artificial intelligence-driven immunogen optimization, are reshaping how we conceive, design, and evaluate vaccines. These advances are not only accelerating responses to emerging threats but also unlocking progress against some of the most persistent challenges in global health, including HIV and malaria. After decades of setbacks, next-generation HIV vaccine strategies leveraging broadly neutralizing antibodies and novel immunogen scaffolds are showing renewed promise, while landmark approvals of malaria vaccines mark a critical step forward that must now be matched by concerted efforts for ensuring global implementation and equitable access. IOCV 2027 brings together researchers, clinicians, and public health practitioners to address these scientific frontiers alongside the practical realities of vaccine deployment, uptake, and impact in diverse populations.
The IOCV 2027 invites researchers from academia, as well as vaccine practitioners, to contribute original findings, novel ideas, scientific concepts, and technological advancements related to the following:
• Advances in Vaccine Platforms and Delivery Systems;
• Innate Immunity, Trained Immunity, and Vaccine Responses;
• Adjuvants and Immune Modulators in Modern Vaccines;
• Vaccines for Chronic and Difficult-to-Control Infections, Including HIV and Malaria;
• Correlates of Protection and Systems Vaccinology;
• Emerging Pathogens and Pandemic Preparedness.
As a fully online conference, IOCV 2027 provides a unique opportunity for researchers worldwide to participate without travel constraints, facilitating the real-time exchange of the latest findings and innovative ideas.
Your contributions and engagement are vital to the success of this 4th edition of the IOCV. Together, we have an opportunity to drive progress in overcoming the most pressing challenges in vaccine science today, ranging from conquering HIV and malaria to ensuring that life-saving vaccines reach every corner of the world. We look forward to your participation in shaping the future of vaccine research!
Kind regards,
Prof. Dr. Michael Bukrinsky
The George Washington University, Washington DC, USA
More News about MDPI Conferences
Meet Our Chair
Department of Microbiology, Immunology & Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, USA;Dr. Mikhail Bukrinsky is a biomedical researcher specializing in HIV biology and inflammatory diseases. He earned his MD from Moscow Medical Institute I in 1978 and his PhD from the USSR Academy of Sciences in 1984. His research focuses on understanding the molecular mechanisms of HIV infection, including viral nuclear import, cholesterol metabolism in infected cells, and HIV infection of macrophages. Dr. Bukrinsky has also contributed to the development of anti-HIV compounds and discovered extracellular cyclophilin, a pro-inflammatory factor involved in inflammatory disease pathogenesis. In addition to his research, he is actively involved in international educational collaborations.
Important Dates
8 Nov
2026
8 Dec
2026
2 Mar
2027
Meet Our Speaker
Department of Biomedical Research (DBMR), University Hospital of Bern, Bern, Switzerland;Prof. Martin F. Bachmann is Professor of Immunology at the University of Bern and Visiting Professor of Vaccinology at the University of Oxford. He is an internationally recognized leader in vaccinology and translational vaccine research, with a particular focus on understanding how fundamental principles of immune activation can be harnessed for rational vaccine design. A pioneer in virus-like particle (VLP)-based vaccine technologies, his research has contributed to defining how vaccine architecture, antigen organization, and innate and adaptive immune activation shape the magnitude, quality, and durability of protective immune responses. A major hallmark of Prof. Bachmann’s career has been the translation of mechanistic immunology into vaccines and immunotherapies, with numerous candidates progressing from experimental concepts into clinical proof-of-concept and advanced clinical development. This interface between immune mechanisms, correlates of protection, vaccine design, and clinical translation closely aligns with the themes of Correlates of Protection and Systems Vaccinology. With an h-index of 119, Prof. Bachmann has made a substantial international scientific impact in immunology and vaccinology. Prof. Bachmann studied Cell Biology and obtained his PhD in Immunology at ETH Zurich, where both his diploma and PhD theses received the ETH Silver Medal. He subsequently conducted research at the prestigious Basel Institute for Immunology. He previously served as CSO of Cytos Biotechnology and has founded and co-founded several biotechnology companies, further reflecting his long-standing commitment to translational vaccinology and bringing vaccine technologies from academic discovery toward clinical application. In recognition of his scientific achievements and long-standing collaboration with Latvian biomedical research, he was awarded an Honorary Doctorate by the University of Latvia in 2021.
Ms. Peiqi Luo
Ms. Vivien Zhang
Ms. Ann Li
Dr. Maria-Bianca Irimes
Email: iocv2027@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.